Zydus and Synthon to Commercialise Novel 505(B)(2) Oncology Product in US
Under the terms of this agreement, Synthon will be responsible for the development, manufacturing and supply of the finished product.
Global Pharma | 13/02/2025 | By Aishwarya | 619
Oramed to Accelerate Development and Commercialization of Oral Insulin
As part of the transaction, Oramed will transfer its proprietary oral insulin and POD™ technology, along with other pipeline assets, into OraTech.
Global Pharma | 13/02/2025 | By Aishwarya | 419
Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an international multicenter Phase 2 clinical trial.
Global Pharma | 12/02/2025 | By Manvi | 442
Alloy Therapeutics and Pfizer to Develop New Antibody Discovery Platform
Pfizer and Alloy have collaborated on various antibody discovery efforts, including the use of Alloy's ATX-CLC platform.
Global Pharma | 12/02/2025 | By Aishwarya | 264
Novartis to Acquire Anthos Therapeutics for USD 925 Million Upfront
Anthos Therapeutics, launched by Blackstone Life Sciences and Novartis in 2019, has advanced abelacimab through clinical development under a license from Novartis.
Global Pharma | 12/02/2025 | By Aishwarya | 477
Everest Group Recognises Indegene as Front-Runner in GenAI Life Sciences Market Adoption
The report highlights how Indegene’s holistic GenAI strategy and enterprise-grade, production-ready solutions are helping life sciences companies streamline operations and realize strong productivity improvements across several use cases, spanning the clinical, medical and commercial elements of the life sciences value chain.
Global Pharma | 12/02/2025 | By Aishwarya | 289
Synexa Life Sciences Achieves 'My Green Lab Certification'
Synexa Life Sciences, a global provider of biomarker and bioanalytical solutions to the pharmaceutical, biotech, and CRO industries, has achieved the My Green Lab Certification at the highest ‘Green’ level at its Cape Town, South Africa facility.
Global Pharma | 11/02/2025 | By Manvi | 439
Frontier Scientific Begins Construction of cGMP Facilities at Wilmington Airport
Frontier Scientific Solutions announce that construction of its state-of-the-art cGMP temperature-controlled facilities at Wilmington International Airport (ILM) is in full swing with the first vertical structures being installed.
Global Pharma | 11/02/2025 | By Manvi | 229
Recipharm Expands Aseptic Filling Capabilities for Process Development and Clinical Supply
The system offers unmatched flexibility, featuring interchangeable modules that support various product types, such as syringes and vials.
Global Pharma | 11/02/2025 | By Aishwarya | 625
Accord BioPharma Signs Exclusive US Licensing Deal with Bio-Thera for BAT2506
BAT2506 is a proposed golimumab biosimilar developed by Bio-Thera. Golimumab, a human monoclonal antibody, inhibits the biological activity of tumor necrosis factor alpha (TNF-alpha).
Global Pharma | 11/02/2025 | By Aishwarya | 841
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy